In addition to its potential as a “stand-alone
Post# of 155256
(Total Views: 395)
Posted On: 07/01/2025 12:00:46 PM
Quote:
In addition to its potential as a “stand-alone” agent in oncology,
Glad to see that statement. Not sure if it's true but I've often heard that big pharma likes to see efficacy as a monotherapy, not just in combination, when partnering up or acquiring...
Wish we had a monotherapy arm in our mCRC trial.
(3)
(0)